Global antibiotics market will reach $63.99 billion by 2030, growing by 3.5% annually over 2020-2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.
Highlighted with 86 tables and 93 figures, this 182-page report “Global Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Region.
Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cephalosporin
• Penicillin
• Macrolides
• Fluoroquinolones
• Quinolones
• Monobactam
• Aminoglycosides
• Carbapenem
• Other Drug Classes
Based on Action Mechanism, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms
Based on Drug Origin, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics
Based on Activity Spectrum, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics
Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oral Administration
• Intravenous Administration
• Other Administration Routes
Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Brand Antibiotics
• Generic Antibiotics
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• RoW (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Market Research Methodology 14
1.2.2 Market Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 17
1.2.6 Market Size/Share Estimation 18
1.2.7 Research Limitations 19
1.3 Executive Summary 20
2 Market Overview and Dynamics 23
2.1 Market Size and Forecast 23
2.1.1 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Global Market by Drug Class 41
3.1 Market Overview by Drug Class 41
3.2 Cephalosporin 43
3.3 Penicillin 44
3.4 Macrolides 45
3.5 Fluoroquinolones 46
3.6 Quinolones 47
3.7 Monobactam 48
3.8 Aminoglycosides 49
3.9 Carbapenem 50
3.10 Other Drug Classes 51
4 Segmentation of Global Market by Action Mechanism 52
4.1 Market Overview by Action Mechanism 52
4.2 Cell Wall Synthesis Inhibitors 54
4.3 Mycolic Acid Inhibitors 55
4.4 RNA Synthesis Inhibitors 56
4.5 DNA Synthesis Inhibitors 57
4.6 Protein Synthesis Inhibitors 58
4.7 Other Mechanisms 59
5 Segmentation of Global Market by Drug Origin 60
5.1 Market Overview by Drug Origin 60
5.2 Natural Antibiotics 62
5.3 Semi-synthetic Antibiotics 63
5.4 Synthetic Antibiotics 64
6 Segmentation of Global Market by Activity Spectrum 65
6.1 Market Overview by Activity Spectrum 65
6.2 Broad-spectrum Antibiotics 67
6.3 Narrow-spectrum Antibiotics 68
7 Segmentation of Global Market by Route of Administration 69
7.1 Market Overview by Route of Administration 69
7.2 Oral Administration 71
7.3 Intravenous Administration 72
7.4 Other Administration Routes 73
8 Segmentation of Global Market by Drug Type 74
8.1 Market Overview by Drug Type 74
8.2 Brand Antibiotics 76
8.3 Generic Antibiotics 77
9 Segmentation of Global Market by Region 78
9.1 Geographic Market Overview 2019-2030 78
9.2 North America Market 2019-2030 by Country 84
9.2.1 Overview of North America Market 84
9.2.2 U.S. 88
9.2.3 Canada 92
9.2.4 Mexico 94
9.3 European Market 2019-2030 by Country 96
9.3.1 Overview of European Market 96
9.3.2 Germany 100
9.3.3 UK 102
9.3.4 France 104
9.3.5 Spain 106
9.3.6 Italy 108
9.3.7 Russia 110
9.3.8 Rest of European Market 112
9.4 Asia-Pacific Market 2019-2030 by Country 114
9.4.1 Overview of Asia-Pacific Market 114
9.4.2 Japan 118
9.4.3 China 121
9.4.4 Australia 123
9.4.5 India 125
9.4.6 South Korea 127
9.4.7 Rest of APAC Region 129
9.5 South America Market 2019-2030 by Country 131
9.5.1 Argentina 134
9.5.2 Brazil 136
9.5.3 Chile 138
9.5.4 Rest of South America Market 140
9.6 MEA Market 2019-2030 by Country 141
9.6.1 UAE 144
9.6.2 Saudi Arabia 146
9.6.3 South Africa 148
9.6.4 Other National Markets 150
10 Competitive Landscape 151
10.1 Overview of Key Vendors 151
10.2 New Product Launch, Partnership, Investment, and M&A 155
10.3 Company Profiles 156
Abbott Laboratories 156
Astellas Pharma 158
AstraZeneca Plc 159
Bayer AG 160
Bristol Myers Squibb Company 161
Cipla Inc. 162
Dr. Reddy’s Laboratories Ltd. 163
Eli Lilly and Company 164
F. Hoffmann-La Roche Ltd. 165
Gilead Sciences, Inc. 166
GlaxoSmithKline plc. 167
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 168
Mayne Pharma Group Ltd. 169
MELINTA THERAPEUTICS, INC. 170
Merck KGaA 171
Novartis AG 172
Pfizer Inc. 173
Sanofi 174
Sun Pharmaceutical Industries Ltd. 175
11 Investing in Global Market: Risk Assessment and Management 176
11.1 Risk Evaluation of Global Market 176
11.2 Critical Success Factors (CSFs) 179
Related Reports and Products 182
Table 1. Snapshot of Global Antibiotics Market, 2019-2030 21
Table 2. Main Product Trends and Market Opportunities in Global Antibiotics Market 33
Table 3. Global Antibiotics Market by Drug Class, 2019-2030, $ mn 41
Table 4. Global Antibiotics Market by Action Mechanism, 2019-2030, $ mn 52
Table 5. Global Antibiotics Market by Drug Origin, 2019-2030, $ mn 60
Table 6. Global Antibiotics Market by Activity Spectrum, 2019-2030, $ mn 65
Table 7. Global Antibiotics Market by Route of Administration, 2019-2030, $ mn 69
Table 8. Global Antibiotics Market by Drug Type, 2019-2030, $ bn 74
Table 9. Global Antibiotics Market by Region, 2019-2030, $ bn 79
Table 10. Total Health Expenditure per capita in PPP International U.S. Dollars by Country 81
Table 11. Leading National Antibiotics Market, 2019 and 2030, $ bn 83
Table 12. North America Antibiotics Market by Country, 2019-2030, $ bn 86
Table 13. U.S. Antibiotics Market by Drug Class, 2019-2030, $ mn 90
Table 14. U.S. Antibiotics Market by Drug Origin, 2019-2030, $ mn 90
Table 15. U.S. Antibiotics Market by Route of Administration, 2019-2030, $ mn 90
Table 16. Canada Antibiotics Market by Drug Class, 2019-2030, $ mn 93
Table 17. Canada Antibiotics Market by Drug Origin, 2019-2030, $ mn 93
Table 18. Canada Antibiotics Market by Route of Administration, 2019-2030, $ mn 93
Table 19. Mexico Antibiotics Market by Drug Class, 2019-2030, $ mn 95
Table 20. Mexico Antibiotics Market by Drug Origin, 2019-2030, $ mn 95
Table 21. Mexico Antibiotics Market by Route of Administration, 2019-2030, $ mn 95
Table 22. Europe Antibiotics Market by Country, 2019-2030, $ bn 99
Table 23. Germany Antibiotics Market by Drug Class, 2019-2030, $ mn 101
Table 24. Germany Antibiotics Market by Drug Origin, 2019-2030, $ mn 101
Table 25. Germany Antibiotics Market by Route of Administration, 2019-2030, $ mn 101
Table 26. UK Antibiotics Market by Drug Class, 2019-2030, $ mn 103
Table 27. UK Antibiotics Market by Drug Origin, 2019-2030, $ mn 103
Table 28. UK Antibiotics Market by Route of Administration, 2019-2030, $ mn 103
Table 29. France Antibiotics Market by Drug Class, 2019-2030, $ mn 105
Table 30. France Antibiotics Market by Drug Origin, 2019-2030, $ mn 105
Table 31. France Antibiotics Market by Route of Administration, 2019-2030, $ mn 105
Table 32. Spain Antibiotics Market by Drug Class, 2019-2030, $ mn 107
Table 33. Spain Antibiotics Market by Drug Origin, 2019-2030, $ mn 107
Table 34. Spain Antibiotics Market by Route of Administration, 2019-2030, $ mn 107
Table 35. Italy Antibiotics Market by Drug Class, 2019-2030, $ mn 109
Table 36. Italy Antibiotics Market by Drug Origin, 2019-2030, $ mn 109
Table 37. Italy Antibiotics Market by Route of Administration, 2019-2030, $ mn 109
Table 38. Russia Antibiotics Market by Drug Class, 2019-2030, $ mn 111
Table 39. Russia Antibiotics Market by Drug Origin, 2019-2030, $ mn 111
Table 40. Russia Antibiotics Market by Route of Administration, 2019-2030, $ mn 111
Table 41. Antibiotics Market in Rest of Europe by Country, 2019-2030, $ bn 113
Table 42. APAC Antibiotics Market by Country, 2019-2030, $ bn 116
Table 43. Japan Antibiotics Market by Drug Class, 2019-2030, $ mn 120
Table 44. Japan Antibiotics Market by Drug Origin, 2019-2030, $ mn 120
Table 45. Japan Antibiotics Market by Route of Administration, 2019-2030, $ mn 120
Table 46. China Antibiotics Market by Drug Class, 2019-2030, $ mn 122
Table 47. China Antibiotics Market by Drug Origin, 2019-2030, $ mn 122
Table 48. China Antibiotics Market by Route of Administration, 2019-2030, $ mn 122
Table 49. Australia Antibiotics Market by Drug Class, 2019-2030, $ mn 124
Table 50. Australia Antibiotics Market by Drug Origin, 2019-2030, $ mn 124
Table 51. Australia Antibiotics Market by Route of Administration, 2019-2030, $ mn 124
Table 52. India Antibiotics Market by Drug Class, 2019-2030, $ mn 126
Table 53. India Antibiotics Market by Drug Origin, 2019-2030, $ mn 126
Table 54. India Antibiotics Market by Route of Administration, 2019-2030, $ mn 126
Table 55. South Korea Antibiotics Market by Drug Class, 2019-2030, $ mn 128
Table 56. South Korea Antibiotics Market by Drug Origin, 2019-2030, $ mn 128
Table 57. South Korea Antibiotics Market by Route of Administration, 2019-2030, $ mn 128
Table 58. Antibiotics Market in Rest of APAC by Country, 2019-2030, $ bn 130
Table 59. South America Antibiotics Market by Country, 2019-2030, $ bn 133
Table 60. Argentina Antibiotics Market by Drug Class, 2019-2030, $ mn 135
Table 61. Argentina Antibiotics Market by Drug Origin, 2019-2030, $ mn 135
Table 62. Argentina Antibiotics Market by Route of Administration, 2019-2030, $ mn 135
Table 63. Brazil Antibiotics Market by Drug Class, 2019-2030, $ mn 137
Table 64. Brazil Antibiotics Market by Drug Origin, 2019-2030, $ mn 137
Table 65. Brazil Antibiotics Market by Route of Administration, 2019-2030, $ mn 137
Table 66. Chile Antibiotics Market by Drug Class, 2019-2030, $ mn 139
Table 67. Chile Antibiotics Market by Drug Origin, 2019-2030, $ mn 139
Table 68. Chile Antibiotics Market by Route of Administration, 2019-2030, $ mn 139
Table 69. MEA Antibiotics Market by Country, 2019-2030, $ bn 143
Table 70. UAE Antibiotics Market by Drug Class, 2019-2030, $ mn 145
Table 71. UAE Antibiotics Market by Drug Origin, 2019-2030, $ mn 145
Table 72. UAE Antibiotics Market by Route of Administration, 2019-2030, $ mn 145
Table 73. Saudi Arabia Antibiotics Market by Drug Class, 2019-2030, $ mn 147
Table 74. Saudi Arabia Antibiotics Market by Drug Origin, 2019-2030, $ mn 147
Table 75. Saudi Arabia Antibiotics Market by Route of Administration, 2019-2030, $ mn 147
Table 76. South Africa Antibiotics Market by Drug Class, 2019-2030, $ mn 149
Table 77. South Africa Antibiotics Market by Drug Origin, 2019-2030, $ mn 149
Table 78. South Africa Antibiotics Market by Route of Administration, 2019-2030, $ mn 149
Table 79. Breakdown of Global Market by Key Vendor, 2019, % 153
Table 80. Abbott Laboratories: Company Snapshot 156
Table 81. Abbott Laboratories: Business Segmentation 156
Table 82. Abbott Laboratories: Product Portfolio 157
Table 83. Abbott Laboratories: Revenue, 2016-2018, $ mn 157
Table 84. Abbott Laboratories: Recent Developments 157
Table 85. Risk Evaluation for Investing in Global Market, 2019-2030 177
Table 86. Critical Success Factors and Key Takeaways 180
